



BMJ Open Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis

Arnav Agarwal ^{1,2}, Ya Gao ³, Luis Enrique Colunga Lozano,⁴ Saad Asif,⁵ Layla Bakaa,⁶ Maryam Ghadimi,² John Basmaji,⁷ Aninditee Das,⁸ Mark Loeb,^{2,5} Gordon Guyatt^{2,5}

To cite: Agarwal A, Gao Y, Colunga Lozano LE, *et al*. Shorter versus longer durations of antibiotic treatment for patients with community-acquired pneumonia: a protocol for a systematic review and meta-analysis. *BMJ Open* 2022;**12**:e062428. doi:10.1136/bmjopen-2022-062428

► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online (<http://dx.doi.org/10.1136/bmjopen-2022-062428>).

Received 09 March 2022

Accepted 30 May 2022



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Professor Gordon Guyatt; guyatt@mcmaster.ca

ABSTRACT

Introduction Community-acquired pneumonia (CAP), frequently encountered in both outpatient and inpatient settings, is the leading cause of infectious disease-related mortality. While equipoise regarding the optimal duration of antimicrobial therapy to treat CAP remains, recent studies suggest shorter durations of therapy may achieve optimal outcomes. We have therefore planned a systematic review and meta-analysis evaluating the impact of shorter versus longer durations of antibiotic therapy for patients with CAP.

Methods and analysis We searched Ovid MEDLINE, Embase, CINAHL and Cochrane Central Register of Controlled Trials from inception to September 2021 for randomised controlled trials evaluating shorter versus longer duration of antibiotics. Eligible studies will compare durations with a minimum difference of two days of antibiotic therapy, irrespective of antibiotic agent, class, route, frequency or dosage, and will report on any patient-important outcome of benefit or harm. Paired reviewers working independently will conduct title and abstract screening, full-text screening, data extraction and risk of bias (RoB) evaluation using a modified Cochrane RoB 2.0 tool. We will perform random-effects modelling for meta-analyses, with study weights generated using the inverse variance method, and will assess certainty in effect estimates using Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. The Instrument for assessing the Credibility of Effect Modification Analyses (ICEMAN) tool will inform assessments of credibility of subgroup effects based on severity of illness, drug class, duration of therapy, setting of CAP acquisition and RoB.

Ethics and dissemination The results will be of importance to general practitioners and internists managing CAP, and may directly inform international clinical guidance. Where concerns regarding antimicrobial resistance continue to grow internationally, this evidence summary may motivate new recommendations regarding shorter durations of therapy. We intend to disseminate our findings via national and international conferences, and publication in a peer-reviewed journal.

PROSPERO registration number CRD42021283990.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- ⇒ The planned systematic review will summarise all available evidence relevant to antibiotic duration for community-acquired pneumonia, irrespective of setting (outpatient or inpatient) and severity of illness, with a planned subgroup analysis to address possible effect modification by disease severity.
- ⇒ The review will use a comprehensive search strategy supplemented by reference list screening, will incorporate both published and unpublished data, and will have predefined frameworks for screening, extraction, statistical analysis and subgroup analysis.
- ⇒ The review will evaluate all patient-important outcomes with available data, and will not be limited to prespecified outcomes of interest.
- ⇒ The review will use a validated risk of bias tool, GRADE methodology to systematically evaluate certainty in effect estimates, and the ICEMAN tool to evaluate credibility of subgroup effects.
- ⇒ We have no plans to contact authors about issues of inadequate reporting or confirmation regarding our data abstraction or risk of bias assessments.

INTRODUCTION

Community-acquired pneumonia (CAP) is among the most common illnesses managed in the outpatient setting, frequently requires hospital admission, and constitutes one of the most common indications for antibiotic prescriptions.^{1–4} It is the leading cause of infectious disease-related mortality in high-income countries.⁵ There remains equipoise regarding the optimal duration of antimicrobial therapy to treat CAP in both inpatient and outpatient settings.

Although CAP has traditionally been treated for at least seven days,^{6,7} clinicians are now considering shorter duration of therapy. Guidance from the American Thoracic

Society and Infectious Diseases Society of America published in 2019 provided a strong recommendation, based on moderate-quality evidence, for at least five days of therapy, and continuation of therapy until the patient achieves clinical stability⁵; guidelines from the American College of Physicians published in 2021 recommended the same.⁸ This shift is in keeping with evolving evidence over two decades, which has suggested optimal outcomes may require only five days of therapy.^{9–11}

Recent randomised controlled trials (RCTs) have compared three versus eight days of therapy in both outpatients and those requiring hospital admission for CAP, and have reported satisfactory outcomes of clinical improvement and stability, improved adherence and fewer adverse effects in those receiving the shorter duration.^{12–20} Whether these trials will motivate a change in recommendations remains uncertain.

Shortened duration of antimicrobial therapy may reduce the emergence of antimicrobial resistance, individual and healthcare system-related costs, antibiotic-related side effects and risk of bacterial superinfection. Short courses may, however, be associated with recurrent or refractory illness, and relatedly greater individual and healthcare system-related costs.²¹

Although previous systematic reviews, and overviews of reviews, have examined shorter versus longer duration of therapy for CAP,^{10 11 22–26} they have not evaluated durations less than five days,^{11 23 25} or are limited to a comparison of two durations with the same drug across arms.²⁶ A recent review by Tansarli and colleagues in 2018 found no significant difference in clinical cure, fewer adverse events and lower mortality associated with shorter (\leq six days) versus longer courses of therapy (\geq seven days), irrespective of patient setting or severity of pneumonia. Subgroup analyses comparing three versus five days of therapy found no significant difference in clinical cure or relapse rates.¹⁰

An updated synthesis of evidence may motivate a change in evidence-based clinical guidance. We therefore plan to conduct a systematic review and meta-analysis evaluating the impact of shorter versus longer durations of antibiotic therapy for patients with CAP, including recent RCT evidence comparing durations less than five days with longer courses of treatment.

METHODS AND ANALYSIS

This protocol adheres to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-Protocols standards. We will adhere to the PRISMA checklist for reporting our systematic review and meta-analysis (online supplemental material 1). Our protocol has been registered on PROSPERO (CRD42021283990).

Search strategy

With the aid of a medical librarian, we have conducted a systematic search of the published literature in four electronic databases from inception to present: Ovid MEDLINE (1946–September 2021), Embase

(1947–September 2021), CINAHL (1982–September 2021) and the Cochrane Central Register of Controlled Trials (1991–September 2021).

Search terms include a combination of keywords and medical subject heading terms: “duration of therapy”, “vs”, “days”, “extended”, “limited”, “shorter”, “longer”, “pneumonia”, “respiratory tract infection”, “antibiotic”, “randomized controlled trial” (online supplemental material 2). We did not apply language restrictions in our search.

We will supplement our search by reviewing bibliographies of review articles and eligible trials for additional studies not identified by the electronic searches.

Eligibility criteria

We will include parallel arm RCTs or quasi-randomised studies.

Studies including adults aged 18 years of age or older with a diagnosis of CAP will be eligible. We will accept investigator-defined definitions of CAP, including clinical (confirmed based on signs and symptoms) and radiologically established diagnoses. All severities of CAP will be eligible, including mild, moderate, severe and critical illness. We will not limit eligibility to ‘uncomplicated’ or ‘complicated’ pneumonia, regardless of definition. Studies undertaken in the outpatient setting, and those in hospitalised patients, will both be eligible. Studies involving patients with immunocompromise or other comorbidities will be eligible. We will not limit to specific implicated organisms, and will include both typical and atypical pneumonias and both empirical and pathogen-directed therapies. Pneumonia acquired in other congregate settings such as long-term care facilities and retirement homes will be eligible.

We will exclude studies addressing hospital-acquired pneumonia and those enrolling only patients with Pneumocystis pneumonia. We will include studies enrolling patients we do not consider eligible (eg, under 18 years, having Pneumocystis pneumonia) if the proportion of such patients is 20% or less, or if authors report separately on our population of interest.

We will include studies with at least one arm with antibiotics for a shorter duration, compared with at least one arm with antibiotics for a longer duration. Eligible studies will involve a minimum difference of two days in duration of therapy between two or more arms, without requirement that the shorter and longer duration arms use the same antibiotic regimens, and without restriction regarding frequency, dosage or route of administration.

Eligible studies will report at least one patient-important outcome including, but not limited to, clinical cure or response, overall and pneumonia-related mortality, need for and duration of hospitalisation, need for and duration of intensive care unit admission, hospital readmission, invasive ventilation, relapse, serious adverse events leading to discontinuation and all adverse events.

We will include articles meeting eligibility criteria, irrespective of publication status; specifically, we will include grey literature and conference abstracts.

Study selection

Paired reviewers will independently conduct title and abstract and full-text screening using pretested, standardised screening forms with accompanying instructions. Reviewers will resolve disagreements by discussion; as necessary, a third reviewer (AA) will adjudicate. We will use Covidence (<https://covidence.org/>) for screening.

Data extraction and risk of bias

Paired reviewers will independently extract data and evaluate risk of bias using pretested, standardised extraction forms with accompanying instructions, resolving disagreements by discussion; if necessary, a third reviewer (AA) will adjudicate.

We will extract data on population, interventions, comparators and outcomes of interest. For population, extracted data will include: setting (outpatient vs admission to hospital at baseline); initial severity of illness (mild vs moderate vs severe vs critical); cointerventions; antibiotic administered; dosing, route of administration and frequency; compliance with therapy; radiographic findings and sputum culture positivity.

We will evaluate risk of bias using the modified Cochrane risk of bias 2.0, with judgements classified as 'low', 'probably low', 'probably high' or 'high' for the following domains: bias due to randomisation, bias due to deviations from the intended intervention, bias due to missing outcome data, bias in measurement of the outcome, bias in selection of the reported result and bias due to competing risks. We will assess risk of bias by outcome.

Certainty of the evidence

We will consider the overall certainty in evidence for each outcome using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework, based on the following domains: risk of bias, imprecision, inconsistency, indirectness and publication bias. Overall certainty of evidence will be rated as 'very low', 'low', 'moderate' or 'high'. We will consider rating down the certainty of evidence for risk of bias based on lack of blinding for subjective outcomes only.^{27–29} We will address missing data as part of risk of bias assessments based on a previously published approach.³⁰

Statistical analysis

Given significant variation in patients and interventions may be present, we plan to conduct random-effects modelling for our primary meta-analyses (Cochrane Collaboration, Oxford). In instances where random effects give counterintuitive results, in particular large differences between small and larger studies, we will switch to fixed-effect modelling. All analyses will be performed in RevMan version 5.3 (Cochrane Collaboration, Oxford).

Study weights will be generated using the inverse variance method. We will present dichotomous outcomes as risk ratios, with absolute effects calculated to facilitate interpretation. Baseline risk will be inferred from median values for a given outcome from the control group. We will present continuous outcomes as mean differences or standardised mean differences, all with 95% CIs. We will assume a normal distribution for continuous outcomes, and will convert IQRs to SDs as per guidance from the Cochrane Collaboration. We will assess heterogeneity between studies using the χ^2 test for homogeneity, I^2 measure and visual inspection of the forest plots.

If sufficient data are available, we will plan the following subgroup analyses:

1. Severity of illness: mild versus moderate versus severe versus critical (hypothesis: larger benefit in the longer duration group with increasingly severe disease).
2. Drug class: comparisons in which arms receive agents belonging to the same drug class versus comparisons in which arms receive agents belonging to different drug classes (hypothesis: differences will be greater when the drug classes differ between arms).
3. Shorter durations of therapy: 1 day vs 3 days vs 5 days vs 7 days (all compared with longer durations) (hypothesis: differences will be greater with comparisons involving shorter duration in the shorter duration arm).
4. Setting: nursing home-acquired pneumonia versus pneumonia acquired in other community settings (hypothesis: differences will be greater in studies including patients with nursing home-acquired pneumonia).
5. Risk of bias: low versus high risk of bias studies (hypothesis: differences will be greater in high risk of bias studies).

We will classify patients requiring hospitalisation without intensive care unit-level care as severe illness, and those requiring intensive care unit-level care, vasopressors and/or mechanical ventilation as critical illness.

We will rate the credibility of effect modification analyses using the Instrument for assessing the Credibility of Effect Modification Analyses tool.³¹

Ethics and dissemination

Ethics approval is not required for this systematic review. We plan to disseminate our results through national and international clinical and methods conferences. We also plan to publish our findings in a peer-reviewed journal widely accessed by general practitioners and internists.

Patient and public involvement

The research question was developed with a focus on all patient-important outcomes. Patients and members of the public were not directly involved in the design of this review.

DISCUSSION

The publication of multiple RCTs evaluating three days of antibiotic therapy compared with longer durations

for the treatment of CAP warrants an updated evidence synthesis to inform guideline recommendations and clinical practice.

Our planned systematic review has a number of strengths. First, we will summarise evidence relevant to CAP irrespective of whether treatment is initiated in the outpatient or inpatient setting. Our evaluation will therefore address the effectiveness of shorter versus longer duration across the spectrum of mild to critical illness, with a planned subgroup analysis to address possible effect modification by disease severity. Second, our analysis will account for both interclass and intraclass antibiotic comparisons. Third, we will evaluate all patient-important outcomes and will not limit our analysis *a priori* to specific clinical practice. Fourth, we have used a comprehensive search strategy developed with the aid of a medical librarian, have incorporated both published and unpublished data, and have predefined screening, extraction, statistical analysis and subgroup analysis plans. To ensure comprehensive identification of all eligible literature, we will screen the reference lists of previously conducted systematic reviews. We intend to use a validated risk of bias tool and GRADE methodology to systematically evaluate certainty in effect estimates.

In conclusion, this protocol describes the detailed methodology of a planned systematic review and meta-analysis addressing shorter versus longer durations of antibiotic therapy for CAP. The results will be of importance to general practitioners and internists managing CAP, and may directly inform international clinical guidance. Particularly, given growing concerns regarding antimicrobial resistance, should shorter and longer courses prove similar in their impact on patient-important outcomes, the new evidence may result in new recommendations for shorter durations of therapy.

Author affiliations

¹Division of General Internal Medicine, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada

³Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, Gansu, China

⁴Department of Clinical Medicine, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico

⁵Department of Medicine, McMaster University, Hamilton, Ontario, Canada

⁶Department of Psychology, Neuroscience and Behaviour, McMaster University, Hamilton, Ontario, Canada

⁷Division of Critical Care, Department of Medicine, Western University, London, Ontario, Canada

⁸Department of Medicine, Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada

Twitter Arnav Agarwal @DrArnavAgarwal

Contributors AA and GG drafted the protocol. All coauthors (AA, YG, LECL, SA, LB, MG, JB, AD, ML and GG) reviewed the protocol, provided critical revisions and approved the final version. GG is the guarantor of the review.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

ORCID iDs

Arnav Agarwal <http://orcid.org/0000-0001-5780-725X>

Ya Gao <http://orcid.org/0000-0002-9280-4457>

REFERENCES

- 1 Verma AA, Guo Y, Kwan JL, *et al*. Patient characteristics, resource use and outcomes associated with general internal medicine hospital care: the general medicine inpatient initiative (gemini) retrospective cohort study. *CMAJ Open* 2017;5:E842–9.
- 2 Magill SS, Edwards JR, Beldavs ZG, *et al*. Prevalence of antimicrobial use in us acute care hospitals. *JAMA* 2014;312:1438–46.
- 3 Jain S, Self WH, Wunderink RG, *et al*. Community-acquired pneumonia requiring hospitalization among U.S. adults. *N Engl J Med* 2015;373:415–27.
- 4 Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015. *Lancet Infect Dis* 2017;17:1133–61.
- 5 Metlay JP, Waterer GW, Long AC, *et al*. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic Society and infectious diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45–67.
- 6 Mandell LA, Marrie TJ, Grossman RF, *et al*. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian infectious diseases Society and the Canadian thoracic Society. The Canadian community-acquired pneumonia Working group. *Clin Infect Dis* 2000;31:383–421.
- 7 Woodhead M, Blasi F, Ewig S, *et al*. Guidelines for the management of adult lower respiratory tract infections--full version. *Clin Microbiol Infect* 2011;17:E1–59.
- 8 Lee RA, Centor RM, Humphrey LL, *et al*. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of physicians. *Ann Intern Med* 2021;174:822–7.
- 9 Dunbar LM, Wunderink RG, Habib MP, *et al*. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. *Clin Infect Dis* 2003;37:752–60.
- 10 Tansarli GS, Mylonakis E, Review S. Systematic review and meta-analysis of the efficacy of short-course antibiotic treatments for community-acquired pneumonia in adults. *Antimicrob Agents Chemother* 2018;62. doi:10.1128/AAC.00635-18. [Epub ahead of print: 27 08 2018].
- 11 Li JZ, Winston LG, Moore DH, *et al*. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. *Am J Med* 2007;120:783–90.
- 12 Dinh A, Ropers J, Duran C, *et al*. Discontinuing β -lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. *Lancet* 2021;397:1195–203.
- 13 el Moussaoui R, de Borgie CAJM, van den Broek P, *et al*. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. *BMJ* 2006;332:1355.
- 14 Rahav G, Fidel J, Gibor Y, *et al*. Azithromycin versus comparative therapy for the treatment of community acquired pneumonia. *Int J Antimicrob Agents* 2004;24:181–4.

- 15 O'Doherty B, Muller O, Randomized MO. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community-acquired pneumonia. azithromycin Study Group. *Eur J Clin Microbiol Infect Dis* 1998;17:828–33.
- 16 Rizzato G, Montemurro L, Fraioli P, *et al.* Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. *Eur Respir J* 1995;8:398–402.
- 17 Schönwald S, Barsić B, Klinar I, *et al.* Three-day azithromycin compared with ten-day roxithromycin treatment of atypical pneumonia. *Scand J Infect Dis* 1994;26:706–10.
- 18 Sopena N, Martínez-Vázquez C, Rodríguez-Suárez JR, *et al.* Comparative study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of community-acquired pneumonia in adults. *J Chemother* 2004;16:102–3.
- 19 Paris R, Confalonieri M, Dal Negro R, *et al.* Efficacy and safety of azithromycin 1 g once daily for 3 days in the treatment of community-acquired pneumonia: an open-label randomised comparison with amoxicillin-clavulanate 875/125 mg twice daily for 7 days. *J Chemother* 2008;20:77–86.
- 20 Gris P. Once-daily, 3-day azithromycin versus a three-times-daily, 10-day course of co-amoxiclav in the treatment of adults with lower respiratory tract infections: results of a randomized, double-blind comparative study. *J Antimicrob Chemother* 1996;37:93–101.
- 21 Spellberg B. The new antibiotic mantra-"shorter is better". *JAMA Intern Med* 2016;176:1254–5.
- 22 Dawson-Hahn EE, Mickan S, Onakpoya I, *et al.* Short-course versus long-course oral antibiotic treatment for infections treated in outpatient settings: a review of systematic reviews. *Fam Pract* 2017;34:511–9.
- 23 Dimopoulos G, Matthaiou DK, Karageorgopoulos DE, *et al.* Short-versus long-course antibacterial therapy for community-acquired pneumonia : a meta-analysis. *Drugs* 2008;68:1841–54.
- 24 Furlan L, Erba L, Trombetta L, *et al.* Short- vs long-course antibiotic therapy for pneumonia: a comparison of systematic reviews and guidelines for the SIMI choosing wisely campaign. *Intern Emerg Med* 2019;14:377–94.
- 25 Lan S-H, Lai C-C, Chang S-P, *et al.* Five-day antibiotic treatment for community-acquired bacterial pneumonia: a systematic review and meta-analysis of randomized controlled trials. *J Glob Antimicrob Resist* 2020;23:94–9.
- 26 López-Alcalde J, Rodríguez-Barrientos R, Redondo-Sánchez J, *et al.* Short-course versus long-course therapy of the same antibiotic for community-acquired pneumonia in adolescent and adult outpatients. *Cochrane Database Syst Rev* 2018;9:CD009070.
- 27 Moustgaard H, Clayton GL, Jones HE, *et al.* Impact of blinding on estimated treatment effects in randomised clinical trials: meta-epidemiological study. *BMJ* 2020;368:16802.
- 28 Page MJ, Higgins JPT, Clayton G, *et al.* Empirical evidence of study design biases in randomized trials: systematic review of Meta-Epidemiological studies. *PLoS One* 2016;11:e0159267.
- 29 Savović J, Jones HE, Altman DG, *et al.* Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials. *Ann Intern Med* 2012;157:429–38.
- 30 Guyatt GH, Ebrahim S, Alonso-Coello P, *et al.* Grade guidelines 17: assessing the risk of bias associated with missing participant outcome data in a body of evidence. *J Clin Epidemiol* 2017;87:14–22.
- 31 Schandelmaier S, Briel M, Varadhan R, *et al.* Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses. *CMAJ* 2020;192:E901–6.